Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $2.43 down -0.41% from its previous closing price of $2.44. In other words, the price has decreased by -$0.41 from its previous closing price. On the day, 1.57 million shares were traded. CRDF stock price reached its highest trading level at $2.56 during the session, while it also had its lowest trading level at $2.4.
Ratios:
For a deeper understanding of Cardiff Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.42 and its Current Ratio is at 4.42. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on July 08, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On June 24, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $3.50.
On September 06, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $8.Craig Hallum initiated its Buy rating on September 06, 2024, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 30 ’25 when PACE GARY W bought 275,000 shares for $2.45 per share. The transaction valued at 673,750 led to the insider holds 1,330,676 shares of the business.
PACE GARY W bought 15,000 shares of CRDF for $36,750 on Jul 30 ’25. The Director now owns 1,345,676 shares after completing the transaction at $2.45 per share. On Dec 17 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,752 shares for $5.42 each. As a result, the insider paid 14,905 and bolstered with 65,316 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 162323040 and an Enterprise Value of 91885824. For the stock, the TTM Price-to-Sale (P/S) ratio is 293.93 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 168.598 whereas that against EBITDA is -1.703.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.29, which has changed by 0.056521773 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $5.64, while it has fallen to a 52-week low of $2.09. The 50-Day Moving Average of the stock is -28.38%, while the 200-Day Moving Average is calculated to be -29.14%.
Shares Statistics:
For the past three months, CRDF has traded an average of 1.87M shares per day and 1378140 over the past ten days. A total of 66.53M shares are outstanding, with a floating share count of 61.07M. Insiders hold about 9.11% of the company’s shares, while institutions hold 37.75% stake in the company. Shares short for CRDF as of 1753920000 were 18840200 with a Short Ratio of 10.07, compared to 1751241600 on 18379006. Therefore, it implies a Short% of Shares Outstanding of 18840200 and a Short% of Float of 29.080000000000002.
Earnings Estimates
The current market rating for Cardiff Oncology Inc (CRDF) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.18 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.78 and -$0.98 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.86, with 6.0 analysts recommending between -$0.65 and -$1.05.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for CRDF’s current fiscal year. The highest revenue estimate was $530k, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $427.5k. In the same quarter a year ago, actual revenue was $683k
